Rebecca C Bishop, Nidhi Shanthappa, Sara L Connolly, Pamela A Wilkins, Annette M McCoy
{"title":"Reference intervals for equine fecal calprotectin and calprotectin:protein ratio and preliminary clinical evaluation in horses with colic and colitis.","authors":"Rebecca C Bishop, Nidhi Shanthappa, Sara L Connolly, Pamela A Wilkins, Annette M McCoy","doi":"10.2460/ajvr.24.09.0271","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To establish the reference interval (RI) of fecal calprotectin (fCP) and fCP:protein ratio in the feces of healthy horses and demonstrate preliminary clinical utility for the quantification of intestinal inflammation.</p><p><strong>Methods: </strong>Feces were collected from healthy horses (n = 103) and horses with colic (n = 15) or colitis (n = 13). Feces were suspended in buffer to create fecal supernatant. Fecal calprotectin concentration was determined by ELISA, fecal total protein concentration was determined by bicinchoninic acid assay, and the fCP:protein ratio was calculated. Reference intervals for fCP and fCP:protein ratio were calculated from healthy horses. Descriptive and inferential statistics were performed to evaluate associations between fCP concentration and fCP:protein ratio with group and other clinical features. The study period was from September 20, 2023, through April 20, 2024.</p><p><strong>Results: </strong>The RI for fCP was 0.056 to 0.278 μg/mL; 4 of 13 colitis cases had fCP above the RI. The RI for fCP:protein was 6.6 X 10-6 to 4.9 X 10-5; 5 of 13 colitis cases and 2 of 15 colic cases had fCP:protein above the RI. Horses with colitis had significantly greater fCP (median [quartile 1, quartile 3], 0.234 [0.194, 0.279] μg/mL) than healthy horses (0.196 [0.138, 0.220] μg/mL) or colic cases (0.189 [0.164, 0.215] μg/mL). There was a greater difference in fCP:protein ratio between colitis cases (4.31 X 10-5 [3.19 X 10-5, 6.23 X 10-5]) and both healthy horses (2.19 X 10-5 [1.58 X 10-5, 2.88 X 10-5]) and colic cases (1.52 X 10-5 [1.22 X 10-5, 3.56 X 10-5]).</p><p><strong>Conclusions: </strong>Both fCP and fCP:protein ratio were increased in horses in colitis; additional work is needed to establish clinical utility.</p><p><strong>Clinical relevance: </strong>There are few reliable diagnostic modalities for inflammation of the equine large colon. With additional development of a clinically applicable test and validation in larger population, fecal calprotectin may facilitate noninvasive quantification of intestinal inflammation in horses.</p>","PeriodicalId":7754,"journal":{"name":"American journal of veterinary research","volume":" ","pages":"1-10"},"PeriodicalIF":1.3000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of veterinary research","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.2460/ajvr.24.09.0271","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To establish the reference interval (RI) of fecal calprotectin (fCP) and fCP:protein ratio in the feces of healthy horses and demonstrate preliminary clinical utility for the quantification of intestinal inflammation.
Methods: Feces were collected from healthy horses (n = 103) and horses with colic (n = 15) or colitis (n = 13). Feces were suspended in buffer to create fecal supernatant. Fecal calprotectin concentration was determined by ELISA, fecal total protein concentration was determined by bicinchoninic acid assay, and the fCP:protein ratio was calculated. Reference intervals for fCP and fCP:protein ratio were calculated from healthy horses. Descriptive and inferential statistics were performed to evaluate associations between fCP concentration and fCP:protein ratio with group and other clinical features. The study period was from September 20, 2023, through April 20, 2024.
Results: The RI for fCP was 0.056 to 0.278 μg/mL; 4 of 13 colitis cases had fCP above the RI. The RI for fCP:protein was 6.6 X 10-6 to 4.9 X 10-5; 5 of 13 colitis cases and 2 of 15 colic cases had fCP:protein above the RI. Horses with colitis had significantly greater fCP (median [quartile 1, quartile 3], 0.234 [0.194, 0.279] μg/mL) than healthy horses (0.196 [0.138, 0.220] μg/mL) or colic cases (0.189 [0.164, 0.215] μg/mL). There was a greater difference in fCP:protein ratio between colitis cases (4.31 X 10-5 [3.19 X 10-5, 6.23 X 10-5]) and both healthy horses (2.19 X 10-5 [1.58 X 10-5, 2.88 X 10-5]) and colic cases (1.52 X 10-5 [1.22 X 10-5, 3.56 X 10-5]).
Conclusions: Both fCP and fCP:protein ratio were increased in horses in colitis; additional work is needed to establish clinical utility.
Clinical relevance: There are few reliable diagnostic modalities for inflammation of the equine large colon. With additional development of a clinically applicable test and validation in larger population, fecal calprotectin may facilitate noninvasive quantification of intestinal inflammation in horses.
期刊介绍：
The American Journal of Veterinary Research supports the collaborative exchange of information between researchers and clinicians by publishing novel research findings that bridge the gulf between basic research and clinical practice or that help to translate laboratory research and preclinical studies to the development of clinical trials and clinical practice. The journal welcomes submission of high-quality original studies and review articles in a wide range of scientific fields, including anatomy, anesthesiology, animal welfare, behavior, epidemiology, genetics, heredity, infectious disease, molecular biology, oncology, pharmacology, pathogenic mechanisms, physiology, surgery, theriogenology, toxicology, and vaccinology. Species of interest include production animals, companion animals, equids, exotic animals, birds, reptiles, and wild and marine animals. Reports of laboratory animal studies and studies involving the use of animals as experimental models of human diseases are considered only when the study results are of demonstrable benefit to the species used in the research or to another species of veterinary interest. Other fields of interest or animals species are not necessarily excluded from consideration, but such reports must focus on novel research findings. Submitted papers must make an original and substantial contribution to the veterinary medicine knowledge base; preliminary studies are not appropriate.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
